Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 34 for:    alpha | linolenic acid

Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02410161
Recruitment Status : Completed
First Posted : April 7, 2015
Results First Posted : February 18, 2019
Last Update Posted : February 18, 2019
Sponsor:
Information provided by (Responsible Party):
Université de Sherbrooke

Brief Summary:

Background: As the main alternative fuel to glucose for the brain, increased plasma ketones could potentially help compensate for brain glucose hypometabolism occurring during aging. The precursor long-chain n-3 polyunsaturated fatty acid (PUFA), α-linolenic acid (ALA), is normally mostly β-oxidized and so could potentially be used to stimulate ketogenesis in humans.

Objective: To compare the impact of an ALA-rich supplement on the ketogenic response in young and older healthy adults.

Design: Ten young and ten older adults will consume a flaxseed oil supplement providing 2 g/d of ALA for 4 weeks. Plasma ketones, free fatty acids, triglycerides, glucose and insulin will be measured over 6 h during two metabolic study days, one before and one at the end of the supplementation.

Hypothesis: ALA-rich supplement for 4 weeks will increase ketone production in both groups.


Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: alpha-linolenic acid-rich supplement Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Dietary Supplement: alpha-linolenic acid-rich supplement
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma n-3 Polyunsaturated Fatty Acids in Young Compared to Older Adults
Study Start Date : July 2013
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 4 week ALA treatment
Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
Dietary Supplement: alpha-linolenic acid-rich supplement
each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).




Primary Outcome Measures :
  1. Ketone Production [ Time Frame: After 4 weeks ]
    Total Ketone (acetoacetate + beta-hydroxybutyrate) concentration in plasma in average during the metabolic study day, measured hourly between 1 and 6h after breakfast


Secondary Outcome Measures :
  1. Plasma Glucose [ Time Frame: After 4 weeks ]
    Glucose measured in plasma in average during the metabolic study day, measure hourly between 0 and 6 h after breakfast

  2. Plasma Triglycerides [ Time Frame: After 4 weeks ]
    Triglycerides measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast

  3. Plasma Free Fatty Acids [ Time Frame: 4 weeks ]
    Free fatty acids measured in plasma in average during the metabolic study day, measured hourly between 1 to 6h after breakfast

  4. Insulin Concentration in Plasma [ Time Frame: after 4 weeks ]
    Insulin measured in plasma in average during the metabolic study day, measured hourly between 0 ans 6 h after breakfast



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • aged between 18 and 30 or 65 years and more

Exclusion Criteria:

  • non smoker
  • pregnancy or breastfeeding
  • diabetes or insulin resistance
  • uncontrolled thyroid disease, hepatic or renal disease
  • uncontrolled high blood pressure
  • medical treatment influencing lipid or glucide metabolism
  • ongoing or past severe drug or alcohol abuse
  • dementia or psychiatric difficulties or depression
  • chronic immune condition or inflammation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02410161


Sponsors and Collaborators
Université de Sherbrooke
Investigators
Layout table for investigator information
Principal Investigator: Stephen Cunnane, PhD Université de Sherbrooke

Layout table for additonal information
Responsible Party: Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT02410161     History of Changes
Other Study ID Numbers: 2014-389
First Posted: April 7, 2015    Key Record Dates
Results First Posted: February 18, 2019
Last Update Posted: February 18, 2019
Last Verified: March 2015
Keywords provided by Université de Sherbrooke:
ketone
α-linolenic acid
flaxseed
aging
β-hydroxybutyrate
acetoacetate
omega-3 fatty acids
ketogenesis